{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T13:43:32Z","timestamp":1776087812171,"version":"3.50.1"},"reference-count":94,"publisher":"Bentham Science Publishers Ltd.","issue":"3","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CRP"],"published-print":{"date-parts":[[2020,11,30]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>FDG PET\/CT imaging has an established role in lung cancer (LC) management.\nWhilst it is a sensitive technique, FDG PET\/CT has a limited specificity in the differentiation\nbetween LC and benign conditions and is not capable of defining LC heterogeneity since FDG uptake\nvaries between histotypes.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Objective:<\/jats:title>\n<jats:p>To get an overview of new radiopharmaceuticals for the study of cancer biology features\nbeyond glucose metabolism in LC.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p>A comprehensive literature review of PubMed\/Medline was performed using a combination\nof the following keywords: \u201cpositron emission tomography\u201d, \u201clung neoplasms\u201d, \u201cnon-FDG\u201d, \u201cradiopharmaceuticals\u201d,\n\u201ctracers\u201d.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>Evidences suggest that proliferation markers, such as 18F-Fluorothymidine and 11CMethionine,\nimprove LC staging and are useful in evaluating treatment response and progression free\nsurvival. 68Ga-DOTA-peptides are already routinely used in pulmonary neuroendocrine neoplasms\n(NENs) management and should be firstly performed in suspected NENs. 18F-Fluoromisonidazole and\nother radiopharmaceuticals show a promising impact on staging, prognosis assessment and therapy\nresponse in LC patients, by visualizing hypoxia and perfusion. Radiolabeled RGD-peptides, targeting\nangiogenesis, may have a role in LC staging, treatment outcome and therapy. PET radiopharmaceuticals\ntracing a specific oncogene\/signal pathway, such as EGFR or ALK, are gaining interest especially\nfor therapeutic implications. Other PET tracers, like 68Ga-PSMA-peptides or radiolabeled FAPIs, need\nmore development in LC, though, they are promising for therapy purposes.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>To date, the employment of most of the described tracers is limited to the experimental\nfield, however, research development may offer innovative opportunities to improve LC staging, characterization,\nstratification and response assessment in an era of increased personalized therapy.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1874471013666191223151402","type":"journal-article","created":{"date-parts":[[2019,12,23]],"date-time":"2019-12-23T12:44:13Z","timestamp":1577105053000},"page":"185-194","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Alternative and New Radiopharmaceutical Agents for Lung Cancer"],"prefix":"10.2174","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8125-4181","authenticated-orcid":true,"given":"Silvi","family":"Telo","sequence":"first","affiliation":[{"name":"Department of Metropolitan Nuclear Medicine, Sant\u2019Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1087-6247","authenticated-orcid":true,"given":"Letizia","family":"Calderoni","sequence":"additional","affiliation":[{"name":"Department of Metropolitan Nuclear Medicine, Sant\u2019Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1664-1032","authenticated-orcid":true,"given":"Sara","family":"Vichi","sequence":"additional","affiliation":[{"name":"Nuclear Engineering Laboratory of Montecuccolino, University of Bologna, Bologna, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9494-754X","authenticated-orcid":true,"given":"Federico","family":"Zagni","sequence":"additional","affiliation":[{"name":"Medical Physics Department, Sant\u2019Orsola-Malpighi hospital, University of Bologna, Bologna, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9215-7579","authenticated-orcid":true,"given":"Paolo","family":"Castellucci","sequence":"additional","affiliation":[{"name":"Department of Metropolitan Nuclear Medicine, Sant\u2019Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1486-2624","authenticated-orcid":true,"given":"Stefano","family":"Fanti","sequence":"additional","affiliation":[{"name":"Department of Metropolitan Nuclear Medicine, Sant\u2019Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.ejca.2018.07.005","volume":"103","author":"Ferlay J.","year":"2018","unstructured":"Ferlay J.; Colombet M.; Soerjomataram I.; Dyba T.; Randi G.; Bettio M.; Gavin A.; Visser O.; Bray F.; Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018. Eur J Cancer 2018,103,356-387","journal-title":"Eur J Cancer"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/S1470-2045(10)70126-1","volume":"12","author":"Brennan P.","year":"2011","unstructured":"Brennan P.; Hainaut P.; Boffetta P.; Genetics of lung-cancer susceptibility. Lancet Oncol 2011,12(4),399-408","journal-title":"Lancet Oncol"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1056\/NEJMoa1616288","volume":"376","author":"Jamal-Hanjani M.","year":"2017","unstructured":"Jamal-Hanjani M.; Wilson G.A.; McGranahan N.; Birkbak N.J.; Watkins T.B.K.; Veeriah S.; Shafi S.; Johnson D.H.; Mitter R.; Rosenthal R.; Salm M.; Horswell S.; Escudero M.; Matthews N.; Rowan A.; Chambers T.; Moore D.A.; Turajlic S.; Xu H.; Lee S.M.; Forster M.D.; Ahmad T.; Hiley C.T.; Abbosh C.; Falzon M.; Borg E.; Marafioti T.; Lawrence D.; Hayward M.; Kolvekar S.; Panagiotopoulos N.; Janes S.M.; Thakrar R.; Ahmed A.; Blackhall F.; Summers Y.; Shah R.; Joseph L.; Quinn A.M.; Crosbie P.A.; Naidu B.; Middleton G.; Langman G.; Trotter S.; Nicolson M.; Remmen H.; Kerr K.; Chetty M.; Gomersall L.; Fennell D.A.; Nakas A.; Rathinam S.; Anand G.; Khan S.; Russell P.; Ezhil V.; Ismail B.; Irvin-Sellers M.; Prakash V.; Lester J.F.; Kornaszewska M.; Attanoos R.; Adams H.; Davies H.; Dentro S.; Taniere P.; O\u2019Sullivan B.; Lowe H.L.; Hartley J.A.; Iles N.; Bell H.; Ngai Y.; Shaw J.A.; Herrero J.; Szallasi Z.; Schwarz R.F.; Stewart A.; Quezada S.A.; Le Quesne J.; Van Loo P.; Dive C.; Hackshaw A.; Swanton C.; TRACERx Consortium Tracking the Evolution of Non-Small-Cell Lung Cancer. N Engl J Med 2017,376(22),2109-2121","journal-title":"N Engl J Med"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"5311","DOI":"10.1200\/JCO.2010.28.8126","volume":"28","author":"Langer C.J.","year":"2010","unstructured":"Langer C.J.; Besse B.; Gualberto A.; Brambilla E.; Soria J-C.; The evolving role of histology in the management of advanced non-small-cell lung cancer. J Clin Oncol 2010,28(36),5311-5320","journal-title":"J Clin Oncol"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1159\/000092080","volume":"73","author":"Fischer B.M.","year":"2006","unstructured":"Fischer B.M.; Mortensen J.; The future in diagnosis and staging of lung cancer: positron emission tomography. Respiration 2006,73(3),267-276","journal-title":"Respiration"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.cpet.2014.07.006","volume":"9","author":"Basu S.","year":"2014","unstructured":"Basu S.; Hess S.; Nielsen Braad P-E.; Olsen B.B.; Inglev S.; H\u00f8ilund-Carlsen P.F.; The Basic Principles of FDG-PET\/CT Imaging. PET Clin 2014,9(4),355-370, v","journal-title":"PET Clin"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1001\/jama.2014.11488","volume":"312","author":"Deppen S.A.","year":"2014","unstructured":"Deppen S.A.; Blume J.D.; Kensinger C.D.; Morgan A.M.; Aldrich M.C.; Massion P.P.; Walker R.C.; McPheeters M.L.; Putnam J.B.; Grogan E.L.; Accuracy of FDG-PET to diagnose lung cancer in areas with infectious lung disease: a meta-analysis. JAMA 2014,312(12),1227-1236","journal-title":"JAMA"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"208","DOI":"10.3389\/fonc.2012.00208","volume":"2","author":"Cuaron J.","year":"2013","unstructured":"Cuaron J.; Dunphy M.; Rimner A.; Role of FDG-PET scans in staging, response assessment, and follow-up care for non-small cell lung cancer. Front Oncol 2013,2,208","journal-title":"Front Oncol"},{"key":"ref=9","author":"Chakraborty R.K.","year":"2018","unstructured":"Chakraborty R.K.; Sharma S.;  Cancer, BronchoalveolarStatPearls 2018","journal-title":"Cancer, BronchoalveolarStatPearls"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.lungcan.2016.01.010","volume":"94","author":"Szyszko T.A.","year":"2016","unstructured":"Szyszko T.A.; Yip C.; Szlosarek P.; Goh V.; Cook G.J.R.; The role of new PET tracers for lung cancer. Lung Cancer 2016,94,7-14","journal-title":"Lung Cancer"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.cpet.2017.09.006","volume":"13","author":"Cheng G.","year":"2018","unstructured":"Cheng G.; Non-Small-Cell Lung Cancer PET Imaging Beyond F18 Fluorodeoxyglucose. PET Clin 2018,13(1),73-81","journal-title":"PET Clin"},{"key":"ref=12","first-page":"1426","volume":"44","author":"Buck A.K.","year":"2003","unstructured":"Buck A.K.; Halter G.; Schirrmeister H.; Kotzerke J.; Wurziger I.; Glatting G.; Mattfeldt T.; Neumaier B.; Reske S.N.; Hetzel M.; Imaging proliferation in lung tumors with PET: 18F-FLT versus 18F-FDG. J Nucl Med 2003,44(9),1426-1431","journal-title":"J Nucl Med"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1007\/s00259-012-2126-8","volume":"39","author":"Yang W.","year":"2012","unstructured":"Yang W.; Zhang Y.; Fu Z.; Sun X.; Mu D.; Yu J.; Imaging proliferation of F-FLT PET\/CT correlated with the expression of microvessel density of tumour tissue in non-small-cell lung cancer. Eur J Nucl Med Mol Imaging 2012,39(8),1289-1296","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1007\/s00259-004-1706-7","volume":"32","author":"Buck A.K.","year":"2005","unstructured":"Buck A.K.; Hetzel M.; Schirrmeister H.; Halter G.; M\u00f6ller P.; Kratochwil C.; Wahl A.; Glatting G.; Mottaghy F.M.; Mattfeldt T.; Neumaier B.; Reske S.N.; Clinical relevance of imaging proliferative activity in lung nodules. Eur J Nucl Med Mol Imaging 2005,32(5),525-533","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"186","DOI":"10.2967\/jnumed.107.044966","volume":"49","author":"Tian J.","year":"2008","unstructured":"Tian J.; Yang X.; Yu L.; Chen P.; Xin J.; Ma L.; Feng H.; Tan Y.; Zhao Z.; Wu W.; A multicenter clinical trial on the diagnostic value of dual-tracer PET\/CT in pulmonary lesions using 3\u2032-deoxy-3\u2032-18F-fluorothymidine and 18F-FDG. J Nucl Med 2008,49(2),186-194","journal-title":"J Nucl Med"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1016\/j.jtcvs.2003.09.003","volume":"127","author":"Halter G.","year":"2004","unstructured":"Halter G.; Buck A.K.; Schirrmeister H.; Wurziger I.; Liewald F.; Glatting G.; Neumaier B.; Sunder-Plassmann L.; Reske S.N.; Hetzel M.; [18F] 3-deoxy-3\u2032-fluorothymidine positron emission tomography: alternative or diagnostic adjunct to 2-[18f]-fluoro-2-deoxy-D-glucose positron emission tomography in the workup of suspicious central focal lesions? J Thorac Cardiovasc Surg 2004,127(4),1093-1099","journal-title":"J Thorac Cardiovasc Surg"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"101","DOI":"10.3892\/mco.2014.440","volume":"3","author":"Li X-F.","year":"2015","unstructured":"Li X-F.; Dai D.; Song X-Y.; Liu J-J.; Zhu Y-J.; Xu W-G.; Comparison of the diagnostic performance of 18F-fluorothymidine versus 18F-fluorodeoxyglucose positron emission tomography on pulmonary lesions: A meta analysis. Mol Clin Oncol 2015,3(1),101-108","journal-title":"Mol Clin Oncol"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1007\/s00259-010-1412-6","volume":"37","author":"Yang W.","year":"2010","unstructured":"Yang W.; Zhang Y.; Fu Z.; Yu J.; Sun X.; Mu D.; Han A.; Imaging of proliferation with 18F-FLT PET\/CT versus 18F-FDG PET\/CT in non-small-cell lung cancer. Eur J Nucl Med Mol Imaging 2010,37(7),1291-1299","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1007\/s00259-013-2632-3","volume":"41","author":"Trigonis I.","year":"2014","unstructured":"Trigonis I.; Koh P.K.; Taylor B.; Tamal M.; Ryder D.; Earl M.; Anton-Rodriguez J.; Haslett K.; Young H.; Faivre-Finn C.; Blackhall F.; Jackson A.; Asselin M.C.; Early reduction in tumour [18F]fluorothymidine (FLT) uptake in patients with non-small cell lung cancer (NSCLC) treated with radiotherapy alone. Eur J Nucl Med Mol Imaging 2014,41(4),682-693","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.2967\/jnumed.113.131631","volume":"55","author":"Everitt S.J.","year":"2014","unstructured":"Everitt S.J.; Ball D.L.; Hicks R.J.; Callahan J.; Plumridge N.; Collins M.; Herschtal A.; Binns D.; Kron T.; Schneider M.; MacManus M.; Differential (18)F-FDG and (18)F-FLT Uptake on Serial PET\/CT Imaging Before and During Definitive Chemoradiation for Non-Small Cell Lung Cancer. J Nucl Med 2014,55(7),1069-1074","journal-title":"J Nucl Med"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1007\/s00259-012-2118-8","volume":"39","author":"Kobe C.","year":"2012","unstructured":"Kobe C.; Scheffler M.; Holstein A.; Zander T.; Nogova L.; Lammertsma A.A.; Boellaard R.; Neumaier B.; Ullrich R.T.; Dietlein M.; Wolf J.; Kahraman D.; Predictive value of early and late residual 18F-fluorodeoxyglucose and 18F-fluorothymidine uptake using different SUV measurements in patients with non-small-cell lung cancer treated with erlotinib. Eur J Nucl Med Mol Imaging 2012,39(7),1117-1127","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref=22","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0132515","volume":"10","author":"Minamimoto R.","year":"2015","unstructured":"Minamimoto R.; Saginoya T.; Kondo C.; Tomura N.; Ito K.; Matsuo Y.; Matsunaga S.; Shuto T.; Akabane A.; Miyata Y.; Sakai S.; Differentiation of Brain Tumor Recurrence from Post-Radiotherapy Necrosis with 11C-Methionine PET: Visual Assessment versus Quantitative Assessment. K. PLoS One 2015,10(7)","journal-title":"PLoS One"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"498","DOI":"10.3171\/jns.2005.103.3.0498","volume":"103","author":"Nariai T.","year":"2005","unstructured":"Nariai T.; Tanaka Y.; Wakimoto H.; Aoyagi M.; Tamaki M.; Ishiwata K.; Senda M.; Ishii K.; Hirakawa K.; Ohno K.; Usefulness of L-[methyl-11C] methionine-positron emission tomography as a biological monitoring tool in the treatment of glioma. J Neurosurg 2005,103(3),498-507","journal-title":"J Neurosurg"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1007\/s12149-007-0142-8","volume":"22","author":"Hsieh H.J.","year":"2008","unstructured":"Hsieh H.J.; Lin S.H.; Lin K.H.; Lee C.Y.; Chang C.P.; Wang S.J.; The feasibility of 11C-methionine-PET in diagnosis of solitary lung nodules\/masses when compared with 18F-FDG-PET. Ann Nucl Med 2008,22(6),533-538","journal-title":"Ann Nucl Med"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1007\/BF02988346","volume":"15","author":"Sasaki M.","year":"2001","unstructured":"Sasaki M.; Kuwabara Y.; Yoshida T.; Nakagawa M.; Koga H.; Hayashi K.; Kaneko K.; Chen T.; Ichiya Y.; Masuda K.; Comparison of MET-PET and FDG-PET for differentiation between benign lesions and malignant tumors of the lung. Ann Nucl Med 2001,15(5),425-431","journal-title":"Ann Nucl Med"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s12149-007-0035-x","volume":"21","author":"Kanegae K.","year":"2007","unstructured":"Kanegae K.; Nakano I.; Kimura K.; Kaji H.; Kuge Y.; Shiga T.; Zhao S.; Okamoto S.; Tamaki N.; Comparison of MET-PET and FDG-PET for differentiation between benign lesions and lung cancer in pneumoconiosis. Ann Nucl Med 2007,21(6),331-337","journal-title":"Ann Nucl Med"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"e49","DOI":"10.1097\/JTO.0000000000000527","volume":"10","author":"Calais J.","year":"2015","unstructured":"Calais J.; Lussato D.; Merlet P.; Reply to \u201c18F-Choline PET-CT in the Management of Lung Cancer and Mucinous Tumors?\u201d. J Thorac Oncol 2015,10(6),e49-e50","journal-title":"J Thorac Oncol"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/pcan.2011.35","volume":"15","author":"Bauman G.","year":"2012","unstructured":"Bauman G.; Belhocine T.; Kovacs M.; Ward A.; Beheshti M.; Rachinsky I.; 18F-fluorocholine for prostate cancer imaging: a systematic review of the literature. Prostate Cancer Prostatic Dis 2012,15(1),45-55","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1081\/DDC-120005622","volume":"28","author":"Lockman P.R.","year":"2002","unstructured":"Lockman P.R.; Allen D.D.; The transport of choline. Drug Dev Ind Pharm 2002,28(7),749-771","journal-title":"Drug Dev Ind Pharm"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"3285","DOI":"10.3892\/mmr.2015.3200","volume":"11","author":"Huang Z.","year":"2015","unstructured":"Huang Z.; Rui J.; Li X.; Meng X.; Liu Q.; Use of C-Choline positron emission tomography\/computed tomography to investigate the mechanism of choline metabolism in lung cancer. Mol Med Rep 2015,11(5),3285-3290","journal-title":"Mol Med Rep"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1007\/s00259-004-1496-y","volume":"31","author":"Tian M.","year":"2004","unstructured":"Tian M.; Zhang H.; Oriuchi N.; Higuchi T.; Endo K.; Comparison of 11C-choline PET and FDG PET for the differential diagnosis of malignant tumors. Eur J Nucl Med Mol Imaging 2004,31(8),1064-1072","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1159\/000074207","volume":"70","author":"Konishi J.","year":"2003","unstructured":"Konishi J.; Yamazaki K.; Tsukamoto E.; Tamaki N.; Onodera Y.; Otake T.; Morikawa T.; Kinoshita I.; Dosaka-Akita H.; Nishimura M.; Mediastinal lymph node staging by FDG-PET in patients with non-small cell lung cancer: analysis of false-positive FDG-PET findings. Respiration 2003,70(5),500-506","journal-title":"Respiration"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1378\/chest.124.3.893","volume":"124","author":"Hara T.","year":"2003","unstructured":"Hara T.; Kosaka N.; Suzuki T.; Kudo K.; Niino H.; Uptake rates of 18F-fluorodeoxyglucose and 11C-choline in lung cancer and pulmonary tuberculosis: a positron emission tomography study. Chest 2003,124(3),893-901","journal-title":"Chest"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1097\/JTO.0000000000000630","volume":"10","author":"Travis W.D.","year":"2015","unstructured":"Travis W.D.; Brambilla E.; Nicholson A.G.; Yatabe Y.; Austin J.H.M.; Beasley M.B.; Chirieac L.R.; Dacic S.; Duhig E.; Flieder D.B.; Geisinger K.; Hirsch F.R.; Ishikawa Y.; Kerr K.M.; Noguchi M.; Pelosi G.; Powell C.A.; Tsao M.S.; Wistuba I.; Panel W.H.O.; WHO Panel. The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification. J Thorac Oncol 2015,10(9),1243-1260","journal-title":"J Thorac Oncol"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1053\/j.semnuclmed.2012.01.002","volume":"42","author":"Baum R.P.","year":"2012","unstructured":"Baum R.P.; Kulkarni H.R.; Carreras C.; Peptides and receptors in image-guided therapy: theranostics for neuroendocrine neoplasms. Semin Nucl Med 2012,42(3),190-207","journal-title":"Semin Nucl Med"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1016\/j.ejrad.2011.03.020","volume":"81","author":"Ambrosini V.","year":"2012","unstructured":"Ambrosini V.; Nicolini S.; Caroli P.; Nanni C.; Massaro A.; Marzola M.C.; Rubello D.; Fanti S.; PET\/CT imaging in different types of lung cancer: an overview. Eur J Radiol 2012,81(5),988-1001","journal-title":"Eur J Radiol"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1007\/s00259-013-2659-5","volume":"41","author":"Venkitaraman B.","year":"2014","unstructured":"Venkitaraman B.; Karunanithi S.; Kumar A.; Khilnani G.C.; Kumar R.; Role of 68Ga-DOTATOC PET\/CT in initial evaluation of patients with suspected bronchopulmonary carcinoid. Eur J Nucl Med Mol Imaging 2014,41(5),856-864","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref=38","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0171301","volume":"12","author":"Walker R.","year":"2017","unstructured":"Walker R.; Deppen S.; Smith G.; Shi C.; Lehman J.; Clanton J.; Moore B.; Burns R.; Grogan E.L.; Massion P.P.; 68Ga-DOTATATE PET\/CT imaging of indeterminate pulmonary nodules and lung cancer. PLoS One 2017,12(2)","journal-title":"PLoS One"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"4501","DOI":"10.12659\/MSM.908545","volume":"24","author":"Li K.","year":"2018","unstructured":"Li K.; Shen M.; Geng H.; Zheng L.; Cao Y.; Computed Tomographic Studies of Noncalcified Nodules Related to Neuroendocrine Lung Tumor Using 68Gallium-Tagged Somatostatin Variant for Improvement in Diagnosis: A Non-Experimental, Non-Randomized, Cross-Sectional Study. Med Sci Monit 2018,24,4501-4509","journal-title":"Med Sci Monit"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1007\/s00259-014-2695-9","volume":"41","author":"Treglia G.","year":"2014","unstructured":"Treglia G.; Giovanella L.; Lococo F.; Evolving role of PET\/CT with different tracers in the evaluation of pulmonary neuroendocrine tu-mours. Eur J Nucl Med Mol Imaging 2014,41(5),853-855","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1111\/crj.12603","volume":"12","author":"Pericleous M.","year":"2018","unstructured":"Pericleous M.; Karpathakis A.; Toumpanakis C.; Lumgair H.; Reiner J.; Marelli L.; Thirlwell C.; Caplin M.E.; Well-differentiated bronchial neuroendocrine tumors: Clinical management and outcomes in 105 patients. Clin Respir J 2018,12(3),904-914","journal-title":"Clin Respir J"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0167-8140(96)91811-3","volume":"41","author":"Nordsmark M.","year":"1996","unstructured":"Nordsmark M.; Overgaard M.; Overgaard J.; Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiother Oncol 1996,41(1),31-39","journal-title":"Radiother Oncol"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1007\/s00259-015-3009-6","volume":"42","author":"Yip C.","year":"2015","unstructured":"Yip C.; Blower P.J.; Goh V.; Landau D.B.; Cook G.J.R.; Molecular imaging of hypoxia in non-small-cell lung cancer. Eur J Nucl Med Mol Imaging 2015,42(6),956-976","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/1471-2407-6-51","volume":"6","author":"Gagel B.","year":"2006","unstructured":"Gagel B.; Reinartz P.; Demirel C.; Kaiser H.J.; Zimny M.; Piroth M.; Pinkawa M.; Stanzel S.; Asadpour B.; Hamacher K.; Coenen H.H.; Buell U.; Eble M.J.; [18F] fluoromisonidazole and [18F] fluorodeoxyglucose positron emission tomography in response evaluation after chemo-\/radiotherapy of non-small-cell lung cancer: a feasibility study. BMC Cancer 2006,6,51","journal-title":"BMC Cancer"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.radonc.2010.10.011","volume":"98","author":"Vera P.","year":"2011","unstructured":"Vera P.; Bohn P.; Edet-Sanson A.; Salles A.; Hapdey S.; Gardin I.; M\u00e9nard J-F.; Modzelewski R.; Thiberville L.; Dubray B.; Simulta-neous positron emission tomography (PET) assessment of metabolism with F-fluoro-2-deoxy-d-glucose (FDG), proliferation with F-fluoro-thymidine (FLT), and hypoxia with fluoro-misonidazole (F-miso) before and during radiotherapy in patients with non-small-cell lung cancer (NSCLC): a pilot study. Radiother Oncol 2011,98(1),109-116","journal-title":"Radiother Oncol"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1177\/1533034615574386","volume":"15","author":"Arvold N.D.","year":"2016","unstructured":"Arvold N.D.; Heidari P.; Kunawudhi A.; Sequist L.V.; Mahmood U.; Tumor hypoxia response after targeted therapy in EGFRmutant non-small cell lung cancer: proof of concept for FMISO-PET. Technol Cancer Res Treat 2016,15(2),234-242","journal-title":"Technol Cancer Res Treat"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.lungcan.2015.11.020","volume":"91","author":"Kinoshita T.","year":"2016","unstructured":"Kinoshita T.; Fujii H.; Hayashi Y.; Kamiyama I.; Ohtsuka T.; Asamura H.; Prognostic significance of hypoxic PET using (18)F-FAZA and (62)Cu-ATSM in non-small-cell lung cancer. Lung Cancer 2016,91,56-66","journal-title":"Lung Cancer"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"e87","DOI":"10.1097\/RLU.0000000000001017","volume":"41","author":"Lopci E.","year":"2016","unstructured":"Lopci E.; Grassi I.; Rubello D.; Colletti P.M.; Cambioli S.; Gamboni A.; Salvi F.; Cicoria G.; Lodi F.; Dazzi C.; Mattioli S.; Fanti S.; Prognostic Evaluation of Disease Outcome in Solid Tumors Investigated With 64Cu-ATSM PET\/CT. Clin Nucl Med 2016,41(2),e87-e92","journal-title":"Clin Nucl Med"},{"key":"ref=49","doi-asserted-by":"publisher","DOI":"10.2214\/AJR.12.9698","volume":"201","author":"Zhang T.","year":"2013","unstructured":"Zhang T.; Das S.K.; Fels D.R.; Hansen K.S.; Wong T.Z.; Dewhirst M.W.; Vlahovic G.; PET with 62Cu-ATSM and 62Cu-PTSM is a useful imaging tool for hypoxia and perfusion in pulmonary lesions. AJR Am J Roentgenol 2013,201(5)","journal-title":"AJR Am J Roentgenol"},{"key":"ref=50","first-page":"106","volume":"46","author":"Piert M.","year":"2005","unstructured":"Piert M.; Machulla H-J.; Picchio M.; Reischl G.; Ziegler S.; Kumar P.; Wester H-J.; Beck R.; McEwan A.J.B.; Wiebe L.I.; Schwaiger M.; Hypoxia-specific tumor imaging with 18F-fluoroazomycin arabinoside. J Nucl Med 2005,46(1),106-113","journal-title":"J Nucl Med"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1080\/0284186X.2017.1329594","volume":"56","author":"Di Perri D.","year":"2017","unstructured":"Di Perri D.; Lee J.A.; Bol A.; Hanin F-X.; Janssens G.; Labar D.; Robert A.; Sterpin E.; Geets X.; Correlation analysis of [18F]fluorodeoxyglucose and [18F]fluoroazomycin arabinoside uptake distributions in lung tumours during radiation therapy. Acta Oncol 2017,56(9),1181-1188","journal-title":"Acta Oncol"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1111\/cas.12771","volume":"106","author":"Saga T.","year":"2015","unstructured":"Saga T.; Inubushi M.; Koizumi M.; Yoshikawa K.; Zhang M-R.; Tanimoto K.; Horiike A.; Yanagitani N.; Ohyanagi F.; Nishio M.; Prognostic value of (18) F-fluoroazomycin arabinoside PET\/CT in patients with advanced non-small-cell lung cancer. Cancer Sci 2015,106(11),1554-1560","journal-title":"Cancer Sci"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"213","DOI":"10.2147\/vhrm.2006.2.3.213","volume":"2","author":"Nishida N.","year":"2006","unstructured":"Nishida N.; Yano H.; Nishida T.; Kamura T.; Kojiro M.; Angiogenesis in cancer. Vasc Health Risk Manag 2006,2(3),213-219","journal-title":"Vasc Health Risk Manag"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"78","DOI":"10.7150\/thno.13242","volume":"6","author":"Chen H.","year":"2016","unstructured":"Chen H.; Niu G.; Wu H.; Chen X.; Clinical Application of Radiolabeled RGD Peptides for PET Imaging of Integrin \u03b1v\u03b23. Theranostics 2016,6(1),78-92","journal-title":"Theranostics"},{"key":"ref=55","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0020070","volume":"2","author":"Haubner R.","year":"2005","unstructured":"Haubner R.; Weber W.A.; Beer A.J.; Vabuliene E.; Reim D.; Sarbia M.; Becker K-F.; Goebel M.; Hein R.; Wester H-J.; Kessler H.; Schwaiger M.; Noninvasive visualization of the activated alphavbeta3 integrin in cancer patients by positron emission tomography and [18F]Galacto-RGD. PLoS Med 2005,2(3)","journal-title":"PLoS Med"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"22","DOI":"10.2967\/jnumed.107.045864","volume":"49","author":"Beer A.J.","year":"2008","unstructured":"Beer A.J.; Lorenzen S.; Metz S.; Herrmann K.; Watzlowik P.; Wester H-J.; Peschel C.; Lordick F.; Schwaiger M.; Comparison of integrin alphaVbeta3 expression and glucose metabolism in primary and metastatic lesions in cancer patients: a PET study using 18F-galacto-RGD and 18F-FDG. J Nucl Med 2008,49(1),22-29","journal-title":"J Nucl Med"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.2967\/jnumed.115.160648","volume":"56","author":"Zheng K.","year":"2015","unstructured":"Zheng K.; Liang N.; Zhang J.; Lang L.; Zhang W.; Li S.; Zhao J.; Niu G.; Li F.; Zhu Z.; Chen X.; 68Ga-NOTA-PRGD2 PET\/CT for Integrin Imaging in Patients with Lung Cancer. J Nucl Med 2015,56(12),1823-1827","journal-title":"J Nucl Med"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"2336","DOI":"10.1007\/s00259-016-3505-3","volume":"43","author":"Luan X.","year":"2016","unstructured":"Luan X.; Huang Y.; Gao S.; Sun X.; Wang S.; Ma L.; Teng X.; Lu H.; Yu J.; Yuan S.; 18F-alfatide PET\/CT may predict short-term outcome of concurrent chemoradiotherapy in patients with advanced non-small cell lung cancer. Eur J Nucl Med Mol Imaging 2016,43(13),2336-2342","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref=59","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0109757","volume":"9","author":"Liang W.","year":"2014","unstructured":"Liang W.; Wu X.; Hong S.; Zhang Y.; Kang S.; Fang W.; Qin T.; Huang Y.; Zhao H.; Zhang L.; Multi-targeted antiangiogenic tyrosine kinase inhibitors in advanced non-small cell lung cancer: meta-analyses of 20 randomized controlled trials and subgroup analyses. PLoS One 2014,9(10)","journal-title":"PLoS One"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1038\/sj.bjc.6605483","volume":"102","author":"Murukesh N.","year":"2010","unstructured":"Murukesh N.; Dive C.; Jayson G.C.; Biomarkers of angiogenesis and their role in the development of VEGF inhibitors. Br J Cancer 2010,102(1),8-18","journal-title":"Br J Cancer"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"285","DOI":"10.2967\/jnumed.115.166462","volume":"57","author":"Luo H.","year":"2016","unstructured":"Luo H.; England C.G.; Graves S.A.; Sun H.; Liu G.; Nickles R.J.; Cai W.; PET Imaging of VEGFR-2 Expression in Lung Cancer with 64Cu-Labeled Ramucirumab. J Nucl Med 2016,57(2),285-290","journal-title":"J Nucl Med"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"797","DOI":"10.2217\/imt-2017-0187","volume":"10","author":"Rossi S.","year":"2018","unstructured":"Rossi S.; Castello A.; Toschi L.; Lopci E.; Immunotherapy in non-small-cell lung cancer: potential predictors of response and new strate-gies to assess activity. Immunotherapy 2018,10(9),797-805","journal-title":"Immunotherapy"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1007\/s11307-017-1060-3","volume":"19","author":"Natarajan A.","year":"2017","unstructured":"Natarajan A.; Mayer A.T.; Reeves R.E.; Nagamine C.M.; Gambhir S.S.; Development of Novel ImmunoPET Tracers to Image Human PD-1 Checkpoint Expression on Tumor-Infiltrating Lymphocytes in a Humanized Mouse Model. Mol Imaging Biol 2017,19(6),903-914","journal-title":"Mol Imaging Biol"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"162","DOI":"10.2967\/jnumed.116.177857","volume":"58","author":"England C.G.","year":"2017","unstructured":"England C.G.; Ehlerding E.B.; Hernandez R.; Rekoske B.T.; Graves S.A.; Sun H.; Liu G.; McNeel D.G.; Barnhart T.E.; Cai W.; Preclinical Pharmacokinetics and Biodistribution Studies of 89Zr-Labeled Pembrolizumab. J Nucl Med 2017,58(1),162-168","journal-title":"J Nucl Med"},{"key":"ref=65","doi-asserted-by":"crossref","first-page":"E6506","DOI":"10.1073\/pnas.1519623112","volume":"112","author":"Maute R.L.","year":"2015","unstructured":"Maute R.L.; Gordon S.R.; Mayer A.T.; McCracken M.N.; Natarajan A.; Ring N.G.; Kimura R.; Tsai J.M.; Manglik A.; Kruse A.C.; Gambhir S.S.; Weissman I.L.; Ring A.M.; Engineering high-affinity PD-1 variants for optimized immunotherapy and immuno-PET imaging. Proc Natl Acad Sci USA 2015,112(47),E6506-E6514","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"504","DOI":"10.6004\/jnccn.2017.0050","volume":"15","author":"Ettinger D.S.","year":"2017","unstructured":"Ettinger D.S.; Wood D.E.; Aisner D.L.; Akerley W.; Bauman J.; Chirieac L.R.; D\u2019Amico T.A.; DeCamp M.M.; Dilling T.J.; Dobelbower M.; Doebele R.C.; Govindan R.; Gubens M.A.; Hennon M.; Horn L.; Komaki R.; Lackner R.P.; Lanuti M.; Leal T.A.; Leisch L.J.; Lilenbaum R.; Lin J.; Loo B.W.; Martins R.; Otterson G.A.; Reckamp K.; Riely G.J.; Schild S.E.; Shapiro T.A.; Stevenson J.; Swanson S.J.; Tauer K.; Yang S.C.; Gregory K.; Hughes M.; Non-Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2017,15(4),504-535","journal-title":"J Natl Compr Canc Netw"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.gene.2005.10.018","volume":"366","author":"Normanno N.","year":"2006","unstructured":"Normanno N.; De Luca A.; Bianco C.; Strizzi L.; Mancino M.; Maiello M.R.; Carotenuto A.; De Feo G.; Caponigro F.; Salomon D.S.; Epidermal growth factor receptor (EGFR) signaling in cancer. Gene 2006,366(1),2-16","journal-title":"Gene"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1759-7714.2010.00035.x","volume":"2","author":"Su Z.","year":"2011","unstructured":"Su Z.; Epidermal growth factor receptor mutation-guided treatment for lung cancers: Where are we now? Thorac Cancer 2011,2(1),1-6","journal-title":"Thorac Cancer"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1007\/s11912-017-0560-2","volume":"19","author":"Liao B-C.","year":"2017","unstructured":"Liao B-C.; Lin C-C.; Yang J.C-H.; Novel EGFR Inhibitors in Non-small Cell Lung Cancer: Current Status of Afatinib. Curr Oncol Rep 2017,19(1),4","journal-title":"Curr Oncol Rep"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.1038\/bjc.2011.493","volume":"105","author":"Memon A.A.","year":"2011","unstructured":"Memon A.A.; Weber B.; Winterdahl M.; Jakobsen S.; Meldgaard P.; Madsen H.H.T.; Keiding S.; Nexo E.; Sorensen B.S.; PET imaging of patients with non-small cell lung cancer employing an EGF receptor targeting drug as tracer. Br J Cancer 2011,105(12),1850-1855","journal-title":"Br J Cancer"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1111\/resp.12083","volume":"18","author":"Putora P.M.","year":"2013","unstructured":"Putora P.M.; Fr\u00fch M.; M\u00fcller J.; FDG-PET SUV-max values do not correlate with epidermal growth factor receptor mutation status in lung adenocarcinoma. Respirology 2013,18(4),734-735","journal-title":"Respirology"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1634\/theoncologist.2010-0300","volume":"16","author":"Mak R.H.","year":"2011","unstructured":"Mak R.H.; Digumarthy S.R.; Muzikansky A.; Engelman J.A.; Shepard J-A.O.; Choi N.C.; Sequist L.V.; Role of 18F-fluorodeoxyglucose positron emission tomography in predicting epidermal growth factor receptor mutations in non-small cell lung cancer. Oncologist 2011,16(3),319-326","journal-title":"Oncologist"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s12032-008-9160-1","volume":"27","author":"Huang C-T.","year":"2010","unstructured":"Huang C-T.; Yen R-F.; Cheng M-F.; Hsu Y-C.; Wei P-F.; Tsai Y-J.; Tsai M-F.; Shih J-Y.; Yang C-H.; Yang P-C.; Correlation of F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value and EGFR mutations in advanced lung adenocarcinoma. Med Oncol 2010,27(1),9-15","journal-title":"Med Oncol"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.2967\/jnumed.111.092874","volume":"52","author":"Meng X.","year":"2011","unstructured":"Meng X.; Loo B.W.; Ma L.; Murphy J.D.; Sun X.; Yu J.; Molecular imaging with 11C-PD153035 PET\/CT predicts survival in non-small cell lung cancer treated with EGFR-TKI: a pilot study. J Nucl Med 2011,52(10),1573-1579","journal-title":"J Nucl Med"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.phrs.2017.01.007","volume":"117","author":"Roskoski R.","year":"2017","unstructured":"Roskoski R.; Jr Anaplastic lymphoma kinase (ALK) inhibitors in the treatment of ALK-driven lung cancers. Pharmacol Res 2017,117,343-356","journal-title":"Pharmacol Res"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"e34","DOI":"10.1097\/RLU.0000000000000581","volume":"40","author":"Jeong C.J.","year":"2015","unstructured":"Jeong C.J.; Lee H.Y.; Han J.; Jeong J.Y.; Lee K.S.; Choi Y-L.; Choi J.Y.; Role of imaging biomarkers in predicting anaplastic lymphoma kinase-positive lung adenocarcinoma. Clin Nucl Med 2015,40(1),e34-e39","journal-title":"Clin Nucl Med"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.lungcan.2012.11.021","volume":"79","author":"Choi H.","year":"2013","unstructured":"Choi H.; Paeng J.C.; Kim D-W.; Lee J.K.; Park C.M.; Kang K.W.; Chung J-K.; Lee D.S.; Metabolic and metastatic characteristics of ALK-rearranged lung adenocarcinoma on FDG PET\/CT. Lung Cancer 2013,79(3),242-247","journal-title":"Lung Cancer"},{"key":"ref=78","doi-asserted-by":"publisher","DOI":"10.1101\/mcs.a001115","volume":"3","author":"Holla V.R.","year":"2017","unstructured":"Holla V.R.; Elamin Y.Y.; Bailey A.M.; Johnson A.M.; Litzenburger B.C.; Khotskaya Y.B.; Sanchez N.S.; Zeng J.; Shufean M.A.; Shaw K.R.; Mendelsohn J.; Mills G.B.; Meric-Bernstam F.; Simon G.R.; ALK: a tyrosine kinase target for cancer therapy. Cold Spring Harb Mol Case Stud 2017,3(1)","journal-title":"Cold Spring Harb Mol Case Stud"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1002\/jlcr.3373","volume":"59","author":"Perera S.","year":"2016","unstructured":"Perera S.; Piwnica-Worms D.; Alauddin M.M.; Synthesis of a [(18)F]-labeled ceritinib analogue for positron emission tomography of anaplastic lymphoma kinase, a receptor tyrosine kinase, in lung cancer. J Labelled Comp Radiopharm 2016,59(3),103-108","journal-title":"J Labelled Comp Radiopharm"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.2174\/092986712799462612","volume":"19","author":"Foss C.A.","year":"2012","unstructured":"Foss C.A.; Mease R.C.; Cho S.Y.; Kim H.J.; Pomper M.G.; GCPII imaging and cancer. Curr Med Chem 2012,19(9),1346-1359","journal-title":"Curr Med Chem"},{"key":"ref=81","first-page":"4055","volume":"58","author":"Liu H.","year":"1998","unstructured":"Liu H.; Rajasekaran A.K.; Moy P.; Xia Y.; Kim S.; Navarro V.; Rahmati R.; Bander N.H.; Constitutive and antibody-induced internalization of prostate-specific membrane antigen. Cancer Res 1998,58(18),4055-4060","journal-title":"Cancer Res"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1038\/nrurol.2016.26","volume":"13","author":"Maurer T.","year":"2016","unstructured":"Maurer T.; Eiber M.; Schwaiger M.; Gschwend J.E.; Current use of PSMA-PET in prostate cancer management. Nat Rev Urol 2016,13(4),226-235","journal-title":"Nat Rev Urol"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/j.nucmedbio.2016.08.006","volume":"43","author":"Pillai M.R.A.","year":"2016","unstructured":"Pillai M.R.A.; Nanabala R.; Joy A.; Sasikumar A.; Russ Knapp F.F.; Radiolabeled enzyme inhibitors and binding agents targeting PSMA: Effective theranostic tools for imaging and therapy of prostate cancer. Nucl Med Biol 2016,43(11),692-720","journal-title":"Nucl Med Biol"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1007\/s00259-012-2298-2","volume":"40","author":"Afshar-Oromieh A.","year":"2013","unstructured":"Afshar-Oromieh A.; Malcher A.; Eder M.; Eisenhut M.; Linhart H.G.; Hadaschik B.A.; Holland-Letz T.; Giesel F.L.; Kratochwil C.; Haufe S.; Haberkorn U.; Zechmann C.M.; PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur J Nucl Med Mol Imaging 2013,40(4),486-495","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1007\/s00259-012-2069-0","volume":"39","author":"Afshar-Oromieh A.","year":"2012","unstructured":"Afshar-Oromieh A.; Haberkorn U.; Eder M.; Eisenhut M.; Zechmann C.M.; [68Ga]Gallium-labelled PSMA ligand as superior PET tracer for the diagnosis of prostate cancer: comparison with 18F-FECH. Eur J Nucl Med Mol Imaging 2012,39(6),1085-1086","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1007\/s00259-016-3419-0","volume":"43","author":"Afshar-Oromieh A.","year":"2016","unstructured":"Afshar-Oromieh A.; Hetzheim H.; K\u00fcbler W.; Kratochwil C.; Giesel F.L.; Hope T.A.; Eder M.; Eisenhut M.; Kopka K.; Haberkorn U.; Radiation dosimetry of (68)Ga-PSMA-11 (HBED-CC) and preliminary evaluation of optimal imaging timing. Eur J Nucl Med Mol Imaging 2016,43(9),1611-1620","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1097\/MNM.0000000000000290","volume":"36","author":"Kabasakal L.","year":"2015","unstructured":"Kabasakal L.; Demirci E.; Ocak M.; Akyel R.; Nematyazar J.; Aygun A.; Halac M.; Talat Z.; Araman A.; Evaluation of PSMA PET\/CT imaging using a 68Ga-HBED-CC ligand in patients with prostate cancer and the value of early pelvic imaging. Nucl Med Commun 2015,36(6),582-587","journal-title":"Nucl Med Commun"},{"key":"ref=88","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0186280","volume":"12","author":"Schmidt L.H.","year":"2017","unstructured":"Schmidt L.H.; Heitk\u00f6tter B.; Schulze A.B.; Schliemann C.; Steinestel K.; Trautmann M.; Marra A.; Hillejan L.; Mohr M.; Evers G.; Wardelmann E.; Rahbar K.; G\u00f6rlich D.; Lenz G.; Berdel W.E.; Hartmann W.; Wiewrodt R.; Huss S.; Prostate specific membrane antigen (PSMA) expression in non-small cell lung cancer. PLoS One 2017,12(10)","journal-title":"PLoS One"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"367","DOI":"10.2967\/jnumed.115.164442","volume":"57","author":"Pyka T.","year":"2016","unstructured":"Pyka T.; Weirich G.; Einspieler I.; Maurer T.; Theisen J.; Hatzichristodoulou G.; Schwamborn K.; Schwaiger M.; Eiber M.; 68Ga-PSMA-HBED-CC PET for Differential Diagnosis of Suggestive Lung Lesions in Patients with Prostate Cancer. J Nucl Med 2016,57(3),367-371","journal-title":"J Nucl Med"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1097\/RLU.0000000000001139","volume":"41","author":"Shetty D.","year":"2016","unstructured":"Shetty D.; Loh H.; Bui C.; Mansberg R.; Stevanovic A.; Elevated 68Ga Prostate-Specific Membrane Antigen Activity in Metastatic Non-Small Cell Lung Cancer. Clin Nucl Med 2016,41(5),414-416","journal-title":"Clin Nucl Med"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1097\/RLU.0000000000001935","volume":"43","author":"Jochumsen M.R.","year":"2018","unstructured":"Jochumsen M.R.; Gormsen L.C.; Nielsen G.L.; 68Ga-PSMA Avid Primary Adenocarcinoma of the Lung With Complementary Low 18F-FDG Uptake. Clin Nucl Med 2018,43(2),117-119","journal-title":"Clin Nucl Med"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1007\/s00259-017-3882-2","volume":"45","author":"Virgolini I.","year":"2018","unstructured":"Virgolini I.; Decristoforo C.; Haug A.; Fanti S.; Uprimny C.; Current status of theranostics in prostate cancer. Eur J Nucl Med Mol Imaging 2018,45(3),471-495","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.2967\/jnumed.118.210435","volume":"59","author":"Loktev A.","year":"2018","unstructured":"Loktev A.; Lindner T.; Mier W.; Debus J.; Altmann A.; J\u00e4ger D.; Giesel F.; Kratochwil C.; Barthe P.; Roumestand C.; Haberkorn U.; A Tumor-Imaging Method Targeting Cancer-Associated Fibroblasts. J Nucl Med 2018,59(9),1423-1429","journal-title":"J Nucl Med"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s40658-016-0144-5","volume":"3","author":"Conti M.","year":"2016","unstructured":"Conti M.; Eriksson L.; Physics of pure and non-pure positron emitters for PET: a review and a discussion. EJNMMI Phys 2016,3(1),8","journal-title":"EJNMMI Phys"}],"container-title":["Current Radiopharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eurekaselect.com\/article\/download\/177724","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/177724\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/eurekaselect.com\/article\/download\/177724","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,22]],"date-time":"2021-07-22T19:27:34Z","timestamp":1626982054000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/177724\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,30]]},"references-count":94,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,11,30]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1874471013666191223151402","relation":{},"ISSN":["1874-4710"],"issn-type":[{"value":"1874-4710","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11,30]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2019-01-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-01-27","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-11-11","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-11-30","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}